A phase 1 study to evaluate the feasibility and efficacy of the addition of ropeginterferon alpha‐2b to imatinib treatment in patients with chronic phase chronic myeloid leukemia (CML) not achieving a deep molecular response (molecular remission 4.5)—AGMT_CML 1

Sonja Heibl(Klinikum Wels-Grieskirchen), Josef Thaler(Thrombolysis in Myocardial Infarction Study Group), Dominik Wolf‎(Universität Innsbruck), Richard Greil(Paracelsus Medical University), Thomas Lion(Ludwig Boltzmann Institute for Cancer Research), Gerald Webersinke(AGO Austria), Veronika Buxhofer‐Ausch(Johannes Kepler University of Linz), Thomas Melchardt(Paracelsus Medical University), Stefan Schmidt(Innsbruck Medical University), Thomas Kuehr(Klinikum Wels-Grieskirchen), Gudrun Piringer(Klinikum Wels-Grieskirchen)
Hematological Oncology
August 5, 2020
10.1002/hon.2786
Cited by 11

Related Papers

Development and validation of an International Prognostic Score of thrombosis in World Health Organization–essential thrombocythemia (IPSET-thrombosis)
|Blood|2012|596
Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
|Journal of Clinical Oncology|2011|540
Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients
|Blood|2011|448
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study
|The Lancet Haematology|2020|351
Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial
|The Lancet Infectious Diseases|2021|344